Henna Sawhney

Dr. Henna Sawhney

Centers for Disease Control and Prevention, Atlanta, Georgia, USA
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2022 in Children
Verified
Journal Article
Open access
PDF file
Matthew StollMatthew Stoll
Matthew Stoll
KDKimberly DeQuattro
Kimberly DeQuattro
ZLZhixiu Li
Zhixiu Li
Henna SawhneyHenna Sawhney
Henna Sawhney
PWPamela F. Weiss
Pamela F. Weiss
LGLianne S. Gensler
Lianne S. Gensler
Multiple studies have shown the microbiota to be abnormal in patients with spondyloarthritis (SpA). The purpose of this study was to explore the genetic contributions of these microbiota abnormalities. We analyzed the impact of HLA-B27 on the microbiota of children at risk for SpA and compared the microbiota of HLA-B27+ pediatric offspring of ankylosing spondylitis (AS) patients with that of HLA-B27+ children with SpA. Human DNA was obtained from the offspring for determination of HLA-B27 status and polygenic risk score (PRS). Fecal specimens were collected from both groups for sequencing of the V4 region of the 16S ribosomal RNA gene. Among the offspring of AS patients, there was slight clustering by HLA-B27 status. After adjusting for multiple comparisons, five operational taxonomic units (OTUs) representing three unique taxa distinguished the HLA-B27+ from negative children: Blautia and Coprococcus were lower in the HLA-B27+ offspring, while Faecalibacterium prausnitzii was higher. HLA-B27+ offspring without arthritis were compared to children with treatment-naïve HLA-B27+ SpA. After adjustments, clustering by diagnosis was present. A total of 21 OTUs were significantly associated with diagnosis state, including Bacteroides (higher in SpA patients) and F. prausnitzii (higher in controls). Thus, our data confirmed associations with B. fragilis and F. prausnitzii with juvenile SpA, and also suggest that the mechanism by which HLA-B27 is associated with SpA may not involve alterations of the microbiota.

1 July 2020 in The Journal of Rheumatology
Verified
Journal Article
Closed access
PDF file
JLJean Liew
Jean Liew
JRJohn D. Reveille
John D. Reveille
MCMaria Castillo
Maria Castillo
Henna SawhneyHenna Sawhney
Henna Sawhney
BNBenjamin S. Naovarat
Benjamin S. Naovarat
LGLianne S. Gensler
Lianne S. Gensler
Objective.: Cardiovascular (CV) morbidity and mortality are increased in axial spondyloarthritis (axSpA).We conducted a cross-sectional study evaluating the 10-year atherosclerotic cardiovascular disease (ASCVD) risk in axSpA compared to the general US population.Methods.: We included 211 adults, 40–75 years old with ankylosing spondylitis (AS) or nonradiographic axSpA from 2 sites, who had available data on comorbidities, medication use, blood pressure measures, and laboratory cholesterol values. General population comparators from the 2009–2014 National Health and Examination Survey (NHANES) cycles were matched 4:1 to subjects, on age, sex, and race. We estimated the prevalence ratio for a 10-year ASCVD risk score ≥ 7.5% comparing axSpA and matched NHANES comparators using conditional Poisson regression.Results.: Overall, subjects were 53.9 ± 11.2 years old, 69% were male, and 74% were White. The mean 10-year ASCVD risk score was 6.7 ± 6.9% for those with axSpA, and 9.0 ± 10.5% for NHANES comparators. Compared to those with axSpA, the prevalence of current smoking and diabetes was higher among NHANES comparators. The estimated prevalence ratio for a 10-year ASCVD risk score ≥ 7.5% comparing those with axSpA and their age-, sex-, and race-matched comparators was 0.96 (95% CI 0.74–1.24).Conclusion.: The prevalence of a 10-year ASCVD risk score ≥ 7.5% was not significantly different comparing axSpA patients and those drawn from the general population who were similar in terms of age, sex, and race. Future studies should focus on improved CV risk prediction in axSpA, because underestimation by a general population risk score may potentially explain these results.

27 January 2020 in Headache: The Journal of Head and Face Pain
Verified
Journal Article
Closed access
NRNina Riggins
Nina Riggins
AEAnnika Ehrlich
Annika Ehrlich
Henna SawhneyHenna Sawhney
Henna Sawhney
LDLaura Dapkus
Laura Dapkus
MLMorris Levin
Morris Levin

2 August 2022 in Children
Verified
Journal Article
Open access
PDF file
Matthew StollMatthew Stoll
Matthew Stoll
KDKimberly DeQuattro
Kimberly DeQuattro
ZLZhixiu Li
Zhixiu Li
Henna SawhneyHenna Sawhney
Henna Sawhney
PWPamela F. Weiss
Pamela F. Weiss
LGLianne S. Gensler
Lianne S. Gensler
The authors wish to make the following correction to this paper

1 January 2020 in Cephalalgia Reports
Verified
Journal Article
Open access
PDF file
NRNina Riggins
Nina Riggins
RCRicky Chae
Ricky Chae
MLMorris Levin
Morris Levin
AEAnnika Ehrlich
Annika Ehrlich
Henna SawhneyHenna Sawhney
Henna Sawhney
Peter GoadsbyPeter Goadsby
Peter Goadsby
The objectives of the study are to investigate the incidence of new or worsening headache after cochlear implant (CI) surgery and activation and to determine whether there are predictors of associated headache. We performed a cross-sectional survey of patients who had CI surgery. The frequency and severity of headache, onset of headache relative to surgery and device activation, medication use, family history, headache triggers, and accompanying cranial autonomic symptoms were recorded and analyzed. Thirty-seven subjects were enrolled. In the time period after CI surgery but before CI activation, none reported a new headache and four (11%) reported a worsening headache. After CI activation, six (16%) developed new headache and five (14%) developed worsening headache. These 11 subjects also experienced a significantly higher mean of 6.3 headache days/month following CI activation (p < 0.009). Providers should be aware that new or worsening headache can be reported following CI activation, although not immediately following CI surgery.